Svior Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 20-12-2024
- Paid Up Capital ₹ 0.90 M
as on 20-12-2024
- Company Age 29 Year, 22 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
as on 20-12-2024
- Revenue 10.22%
(FY 2022)
- Profit -41.58%
(FY 2022)
- Ebitda 528.74%
(FY 2022)
- Net Worth 0.85%
(FY 2022)
- Total Assets 0.67%
(FY 2022)
About Svior Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.90 M.
The company currently has active open charges totaling ₹1.00 M.
Samir Kumar and Shalender Banga serve as directors at the Company.
- CIN/LLPIN
U74899DL1995PTC074266
- Company No.
074266
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Dec 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Svior Pharmaceuticals Private Limited offer?
Svior Pharmaceuticals Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Ayurvedic Medicine, Ayurvedic,Herbal Drops & Concentrates, Ayurvedic Immunity Booster, Ayurvedic & Herbal Health Supplement, Herbal Juice.
Who are the key members and board of directors at Svior Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Samir Kumar  | Whole-Time Director | 01-Dec-1995 | Current |
| Shalender Banga | Whole-Time Director | 01-Dec-1995 | Current |
Financial Performance of Svior Pharmaceuticals.
Svior Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 10.22% increase. The company also saw a substantial fall in profitability, with a 41.58% decrease in profit. The company's net worth moved up by a moderate rise of 0.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Svior Pharmaceuticals?
In 2021, Svior Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Aug 2004 | ₹1.00 M | Open |
How Many Employees Work at Svior Pharmaceuticals?
Unlock and access historical data on people associated with Svior Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Svior Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Svior Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
